T-2 toxin is a trichothecene mycotoxin produced by Fusarium species, and it is far from a niche problem. According to the 2018 Biomin Global Report cited by the researchers, among 8,721 agricultural product samples from 75 countries, the average concentration of T-2 toxin was 25 micrograms per kilogram, with detection rates reaching up to 23 percent. International guidelines cap permissible daily intake at 100 nanograms per kilogram of body weight. Once ingested through contaminated food or feed, the toxin can persist in animal tissues, meat, eggs and milk, posing risks along the entire food chain and raising the possibility of serious conditions such as alimentary toxic aleukia and Kaschin-Beck disease. Previous work has linked T-2 exposure to immunotoxicity, neurotoxicity, cardiotoxicity, reproductive toxicity and nephrotoxicity, largely through its capacity to trigger oxidative stress, disrupt mitochondrial protein synthesis and provoke runaway inflammation.

To test whether lycopene could counter these effects, the team, led by Saber Y. Adam and corresponding author Demin Cai of Yangzhou University along with collaborators from several institutions in China, Sudan, Egypt and South Korea, worked with 20 male BALB/c mice, six weeks old and weighing on average 23.5 grams. The animals were randomly assigned to four groups of five: an untreated control group, a lycopene-only group receiving 100 micrograms per kilogram of body weight, a T-2 group receiving the toxin at 200 micrograms per kilogram, and a combined group given lycopene four hours after T-2 exposure. Doses were delivered in sunflower oil by oral gavage every two days for 35 days. Over the five-week course, the researchers tracked body weight, feed and water intake, collected blood and fecal samples, and analyzed gut microbial communities through 16S rRNA sequencing alongside a battery of inflammatory, oxidative and metabolic assays.

The simplest measures told a stark story. Mice exposed to T-2 toxin lost weight and ate and drank less than controls, classic hallmarks of poisoning. Lycopene supplementation largely reversed these losses, restoring body weight gains and normalizing consumption patterns. Microscopic examination of the ileum, the final stretch of the small intestine and the first major barrier the toxin encounters, revealed the structural damage behind the decline: villi, the finger-like projections that multiply the gut’s absorptive surface, were shortened and widened, and crypts were deepened in T-2-exposed animals. Mice that also received lycopene showed significantly taller villi, healthier villus-to-crypt ratios and reduced crypt depth and villus width, indicating that the carotenoid helped preserve the architecture of the intestinal lining that mycotoxins typically erode.

Deeper inside the gut, the toxin also wreaked havoc on the microbial ecosystem, and lycopene partly repaired it. Alpha-diversity indices, including Shannon, Chao1, Pielou’s evenness and Simpson measures, dropped significantly in T-2-exposed mice but rebounded after lycopene treatment. Beta-diversity analyses using principal coordinates analysis, non-metric multidimensional scaling and UPGMA clustering confirmed that the four groups harbored distinctly different microbial communities, with inter-group differences significantly exceeding intra-group variation across ANOSIM, MRPP and ADONIS tests. At the phylum level, Firmicutes rose and Bacteroidota fell with toxin exposure, while the combined treatment produced a striking enrichment of Clostridiaceae, which surged to 36.37 percent in the T-2 plus lycopene group compared with just over 4 percent of Clostridiales in controls. Linear discriminant analysis effect size profiling showed that T-2 exposure favored potentially problematic taxa such as Bacilli and Staphylococcus, whereas lycopene shifted the landscape toward groups associated with gut health, including Bifidobacterium and Ligilactobacillus in the lycopene-only animals.

The downstream products of these microbes may be the key to the protection. Gut bacteria ferment indigestible fiber into short-chain fatty acids, metabolites that fuel the intestinal lining, maintain barrier integrity, modulate immune responses and influence oxidative stress in organs from brain to kidney. In this study, fecal concentrations of hexanoic, butyric, isobutyric, isovaleric, acetic, propionic, pentanoic and heptanoic acids all fell significantly in T-2-exposed mice, consistent with the idea that toxin-driven dysbiosis cripples microbial fermentation. Lycopene treatment restored these fatty acids to levels significantly higher than those in toxin-only animals, suggesting that the carotenoid helped rehabilitate the metabolic function of the gut community, not merely its taxonomic composition.

The systemic consequences were equally striking. T-2 exposure drove significant increases in the pro-inflammatory cytokines interleukin-1 beta, interleukin-2, interleukin-4, interferon gamma, interleukin-17 and tumor necrosis factor alpha, all of which were significantly reduced by lycopene, with the notable exception of interleukin-6, which remained unchanged across all groups. The toxin also spiked plasma levels of reactive oxygen species and malondialdehyde, a marker of lipid peroxidation, while depleting the antioxidant arsenal: catalase, glutathione, adenosine triphosphate and superoxide dismutase 1 all dropped significantly in poisoned mice. Lycopene supplementation reversed each of these outcomes, lowering oxidative damage markers while restoring antioxidant defenses, a pattern consistent with the compound’s established reputation as a potent quencher of reactive species and guardian of DNA, lipids and lipoproteins.

Correlation analysis wove these threads together into a coherent mechanistic picture, though the researchers caution that the associations are exploratory and do not prove causation. After false discovery rate correction, reactive oxygen species showed a strong positive correlation with the pathobiont Helicobacter and a negative correlation with hexanoic acid, while the antioxidant enzyme SOD1 correlated positively with butyric and acetic acids and negatively with Helicobacter. Bifidobacterium tracked positively with catalase, SOD1 and butyric acid, whereas Staphylococcus was negatively associated with acetic and propionic acids, and butyric acid itself was negatively correlated with malondialdehyde. Taken together, the data suggest that lycopene’s antioxidant benefit is not a standalone biochemical effect but is mechanistically entwined with its ability to foster a healthier microbial community whose fatty acid output bolsters the host’s endogenous defenses. Butyrate in particular is known to activate the Nrf2 pathway, a master regulator of antioxidant gene expression that T-2 toxin actively suppresses.

The authors are candid about the study’s limitations. With only five animals per group, statistical power is constrained, and because T-2 toxin depressed feed and water intake, it remains unclear whether lycopene’s protective effects are direct or partly secondary to improved nutrition and overall recovery. The team notes that future work should employ larger sample sizes and pair-feeding designs to disentangle these possibilities and to validate the findings as more than hypothesis-generating observations. Even so, the convergence of evidence across gut structure, microbial ecology, fatty acid metabolism, inflammatory signaling and redox balance makes a compelling case. As mycotoxin contamination persists as an intractable problem in global agriculture, the prospect that an everyday dietary pigment, abundant in the humble tomato, could shore up the gut microbiome and its protective metabolites against one of the most dangerous trichothecenes offers an appealingly simple line of defense, one that the researchers hope can be translated into practical strategies for preventing T-2-related health problems in both animals and people.

The choice of lycopene as a protective agent builds on a growing body of literature about carotenoids and health. Unlike beta-carotene, lycopene is not converted to vitamin A in the body, yet it is one of the most efficient singlet oxygen quenchers among dietary carotenoids. Its conjugated double-bond structure allows it to neutralize reactive species and protect DNA, lipids and lipoproteins from oxidation, and it is a prominent component of the Mediterranean diet, where tomato consumption has been associated with reduced risks of cardiovascular disease and certain cancers in observational studies.

The gut-centered mechanism proposed in this study fits a broader scientific framework. Approximately 100 trillion bacteria reside in the mammalian gastrointestinal tract, with Firmicutes and Bacteroidota together accounting for more than 90 percent of the community. These microbes synthesize vitamins and amino acids, biotransform bile, and ferment indigestible fiber into short-chain fatty acids that fuel the intestinal mucosa and exert systemic effects on organs including the brain, kidneys and liver. Because SCFAs help regulate immune responses and maintain homeostasis, a toxin-induced collapse of microbial fermentation capacity would be expected to reverberate far beyond the gut wall, which is precisely the pattern the researchers observed.

The study also highlights the self-reinforcing nature of oxidative stress and inflammation. Reactive oxygen species can activate inflammatory signaling pathways such as NF-kappaB and the NLRP3 inflammasome, driving production of cytokines like TNF-alpha and interleukin-1 beta, while immune cells themselves release ROS during inflammatory responses. Breaking this cycle is a recognized therapeutic goal, and the finding that lycopene simultaneously lowered cytokine levels and restored antioxidant enzymes such as catalase, glutathione and superoxide dismutase 1 suggests it acted at multiple points in the loop.

Practically, the work points toward natural compounds as accessible candidates for mitigating mycotoxin-related diseases, complementing conventional approaches like grain screening and detoxification, though translation from mice to livestock and humans will require further validation.

Subject of Research: Protective effects of lycopene against T-2 toxin-induced systemic inflammation and oxidative stress in mice through modulation of gut microbiota and short-chain fatty acids

Article Title: Lycopene mitigates T-2 toxin-induced systemic inflammation and oxidative stress in association with gut microbiota and SCFAs regulation in mice

Article References: Adam, S. Y., Ennab, W., Zhu, C., Yuan, L., Ahmed, A. A., Essa, M. O. A., Husien, H. M., Saleh, A. A., Kim, I. H., Liu, H.-Y., & Cai, D. (2026). Lycopene mitigates T-2 toxin-induced systemic inflammation and oxidative stress in association with gut microbiota and SCFAs regulation in mice. Stress Biology, 6(1), Article 63. https://doi.org/10.1007/s44154-026-00331-3

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00331-3

Keywords: lycopene, T-2 toxin, mycotoxin, oxidative stress, systemic inflammation, gut microbiota, short-chain fatty acids, BALB/c mice, intestinal morphology, cytokines, antioxidant enzymes, Fusarium

The study was conducted by internists Muhammet Ateş and Barış Karagün of the Department of Internal Medicine at Adana City Training and Research Hospital in Adana, Türkiye. Working from the hospital’s anonymized records, the pair assembled a retrospective cohort of 220 adults admitted for treatment of an infected diabetic foot wound. For every patient, they recorded the admission serum concentration of 25-hydroxyvitamin D, the stable storage form of vitamin D that clinical laboratories use as the standard yardstick of vitamin status. Deficiency was defined, in line with conventional thresholds, as a level below 20 nanograms per milliliter. The prevalence result was arresting: 109 of the 220 patients, or 49.5 percent, were vitamin D deficient on the day of admission. In other words, roughly one in every two patients arriving with a diabetic foot infection was already running on empty reserves of a hormone-like nutrient that immune cells depend on.

Diabetic foot infection is among the most feared complications of diabetes, and its biology explains why. Chronically high blood sugar damages peripheral nerves, so patients lose the protective pain sensation that would normally alert them to a blister or small ulcer early. Meanwhile, diabetes narrows and stiffens the arteries of the leg, starving the wound of the oxygen and immune cells that healing requires. Hyperglycemia also handicaps the defenses directly: neutrophils, the frontline white blood cells that engulf bacteria, move, adhere and kill less efficiently when glucose runs high. The result can be an ulcer that progresses from a superficial sore to a deep, bone-invading infection. To standardize comparisons, the researchers graded every infection using the criteria of the International Working Group on the Diabetic Foot and the Infectious Diseases Society of America, which classify infections as mild, moderate or severe according to depth, extent and the presence of a systemic inflammatory response. In this cohort, 103 patients (46.8 percent) had mild infections, 66 (30.0 percent) moderate and 51 (23.2 percent) severe.

The first biomarker, vitamin D, is less a vitamin than a secosteroid hormone. The 25-hydroxyvitamin D measured in the study is produced in the liver and circulates for weeks as the body’s reservoir; the kidneys and, crucially, immune cells themselves convert it into the active hormone 1,25-dihydroxyvitamin D. Immune cells are not bystanders in this system. Macrophages, dendritic cells and lymphocytes carry vitamin D receptors, and when activated vitamin D binds to them, it switches on genes encoding antimicrobial peptides such as cathelicidin—natural antibiotics that disrupt bacterial membranes—while tempering the release of inflammatory cytokines. Deficiency is especially common in type 2 diabetes: excess adipose tissue sequesters the fat-soluble vitamin, chronic hyperglycemia interferes with its activation, and diabetic kidney impairment can blunt the final activation step. A level below 20 ng/mL, the threshold used here, is conventionally read as frank deficiency—a state in which the immune system may be operating without one of its chemical co-pilots.

The second biomarker family is even cheaper: four inflammation indices computed arithmetically from the standard complete blood count that virtually every admitted patient already receives. The neutrophil-to-lymphocyte ratio divides the absolute neutrophil count by the absolute lymphocyte count, capturing the classic signature of acute physiological stress—neutrophils surge into the circulation under cortisol, catecholamines and interleukin-6, while lymphocytes fall. The platelet-to-lymphocyte ratio adds platelets, which climb as part of the inflammatory response. The systemic immune-inflammation index multiplies platelet count by neutrophil count and divides by lymphocyte count, producing a composite gauge of the combined inflammatory armament. The systemic inflammation response index multiplies neutrophils by monocytes—the cells that sustain and orchestrate chronic inflammation—divided by lymphocytes. Because all four indices can be derived from numbers already printed on any admission blood panel, they cost nothing and can be calculated within minutes of arrival, turning routine laboratory output into an immediate readout of the body’s inflammatory temperature.

When the researchers split the cohort by vitamin D status, the deficient group looked sicker across the board. Body mass index averaged 32.1 versus 29.9 kg/m² in the replete group, and long-term glucose control, gauged by glycated hemoglobin (HbA1c), was substantially worse at 9.1 versus 8.3 percent, with both comparisons significant at p < 0.001. The inflammatory indices told the same story: median NLR was 5.7 (interquartile range 4.3–7.3) in deficient patients versus 3.6 (3.0–5.0) in those with adequate vitamin D, while the systemic immune-inflammation index registered 1774.0 (1282.0–2499.0) versus 1042.0 (812.5–1450.0). The most consequential difference was time: deficient patients spent a median of 14.0 days in hospital (interquartile range 12.0–17.0), compared with 10.0 days (8.0–12.0) for the replete. Severe infection was more than three and a half times as common in the deficient group, affecting 36.7 percent versus 9.9 percent. On every measure captured at the bedside, low vitamin D flagged a patient in deeper trouble.

Equally striking was the graded pattern across infection severity. Moving from mild to moderate to severe disease, mean 25-hydroxyvitamin D stepped down in lockstep, from 22.1 ± 4.8 ng/mL in mild cases to 17.1 ± 4.2 ng/mL in severe ones, while median NLR climbed from 3.3 (2.7–4.0) to 8.2 (6.9–9.1), both trends robust at p < 0.001. In epidemiology, such a dose-response gradient is one of the classic signals that an association may be more than statistical noise: the deeper the infection, the lower the vitamin and the hotter the inflammation. Alongside these group comparisons, the team ran correlation analyses, logistic regression, linear regression and receiver operating characteristic analyses, a statistical battery designed to test whether the raw associations would survive once other clinical variables entered the equation.

The decisive results came from the multivariable models. In adjusted logistic regression, two variables emerged as independently associated with severe infection: the admission NLR, with an adjusted odds ratio of 3.06 per unit increase (95 percent confidence interval 2.09–4.48, p < 0.001), and serum albumin, with an adjusted odds ratio of 0.10 per unit increase (95 percent confidence interval 0.01–0.76, p = 0.026). Albumin, the liver’s most abundant export protein, is a negative acute-phase reactant: its concentration falls as inflammation ramps up, as nutrition falters and as damaged vessels leak protein into tissue. A low albumin therefore works as a composite alarm for catabolism, malnutrition and systemic illness—precisely the terrain on which severe diabetic foot infections flourish. Notably, vitamin D deficiency itself dropped out as an independent predictor of severity once other variables were accounted for. For length of stay, however, deficiency held its ground: in adjusted linear regression, vitamin D deficiency carried a coefficient of 0.192 (95 percent confidence interval 0.112–0.273, p < 0.001) and NLR a coefficient of 0.052 (95 percent confidence interval 0.036–0.068, p < 0.001), meaning both remained associated with longer admissions after correction.

The authors are explicit that these are associations, not verdicts on causation. The study was retrospective and single-center, built on anonymized hospital records from one institution; the protocol was approved by the hospital’s ethics committee in March 2026, with informed consent waived under the anonymized design. Reverse causality is a live possibility: systemic infection and inflammation can themselves disturb vitamin D metabolism and suppress its circulating levels, so a low 25-hydroxyvitamin D reading may partly be a consequence of severe illness rather than a contributor to it. Deficiency could also simply be a proxy for the metabolic storm that surrounds diabetic foot disease—obesity, poor long-term glycemic control, malnutrition and reduced mobility all deplete vitamin D while independently worsening outcomes. Ateş and Karagün accordingly frame their results as hypothesis-generating. Their conclusion draws a careful line: elevated admission NLR and hypoalbuminemia may warrant closer assessment for severe infection, while low 25-hydroxyvitamin D should be interpreted as a marker of overall vulnerability rather than a target that correction alone is guaranteed to fix. No vitamin D supplementation was tested.

Even so, the practical signal is difficult to ignore. The two instruments that carried the strongest associations—a white-cell ratio and a vitamin level—are among the cheapest tests in existence, orderable in any emergency department in the world. If prospective studies replicate these findings, an admission checklist for diabetic foot patients could take shape: calculate the NLR, check the albumin, note the vitamin D. Patients with a high ratio and low protein might be routed toward closer monitoring, earlier imaging for deep involvement and more aggressive initial antimicrobial therapy, while deficient patients could simply be expected to stay longer and be planned for accordingly. The study also feeds a broader scientific current: the search for free, computable inflammation gauges that transform routine blood counts into risk stratification. With diabetes prevalence climbing worldwide and foot disease claiming a heavy share of diabetes-related hospital days, a zero-cost warning system read off numbers clinicians already possess is exactly the kind of simple idea with far reach. Whether restoring vitamin D can shorten those fourteen-day stays is a question only intervention trials can answer.

A routine blood count could contain a surprisingly broad warning signal for metabolic syndrome, according to a large analysis of U.S. health data. Researchers examining 15,846 adults who participated in the National Health and Nutrition Examination Survey, or NHANES, from 2013 through 2020 found that people with higher pan-immune-inflammation values were more likely to have metabolic syndrome. The association persisted after the investigators adjusted for a wide range of demographic, lifestyle and clinical factors, suggesting that the relationship was not explained simply by age, sex or body weight. Metabolic syndrome is not a single disease but a cluster of abnormalities—including abdominal obesity, elevated blood pressure, high blood sugar, high triglycerides and reduced levels of protective HDL cholesterol—that together raise the risk of cardiovascular disease, stroke and type 2 diabetes. Of the participants included in the analysis, 3,845 met the study’s definition of metabolic syndrome.

The biomarker at the center of the study, known as the pan-immune-inflammation value, or PIV, is designed to combine information from several types of blood cells into one numerical estimate of systemic inflammatory activity. It is generally calculated using platelet, neutrophil, monocyte and lymphocyte counts: platelet count multiplied by neutrophil count and monocyte count, divided by lymphocyte count. Each component reflects a different aspect of the body’s immune and inflammatory state. Neutrophils and monocytes are innate immune cells that can rise during inflammation, while lymphocytes represent an important arm of adaptive immunity. Platelets participate in clotting but also interact with immune cells and blood-vessel walls. By integrating these measurements, PIV may capture a more complex biological pattern than any one cell count or a simpler ratio such as the neutrophil-to-lymphocyte ratio.

The new analysis does not show that inflammation causes metabolic syndrome, nor does it establish that PIV can diagnose the condition. Instead, it identifies a statistical association in a nationally representative, cross-sectional dataset. The researchers divided participants into four groups, or quartiles, according to their PIV values and compared the prevalence of metabolic syndrome across those groups. They then used weighted statistical models designed to account for the complex sampling structure of NHANES, which combines interviews, physical examinations and laboratory measurements to represent the civilian U.S. population. The investigators applied multivariable logistic regression, sensitivity analyses, subgroup comparisons and restricted cubic spline modeling to explore whether the relationship remained after accounting for potential confounding factors and whether it followed a straight-line pattern.

Across four increasingly adjusted statistical models, higher PIV was consistently linked to greater odds of metabolic syndrome. In the least adjusted model, each increase in the analyzed PIV measure was associated with an odds ratio of 1.19, with a 95 percent confidence interval from 1.13 to 1.26. After additional variables were introduced, the association remained statistically significant: the odds ratios were 1.17, 1.19 and finally 1.12 in the most fully adjusted model. The last estimate had a 95 percent confidence interval of 1.04 to 1.19 and a P value of 0.002. An odds ratio above one indicates higher odds of the outcome, although it should not be interpreted as a direct increase in an individual’s absolute risk. The confidence intervals also indicate uncertainty around each estimate; because they did not cross one, the researchers considered the associations statistically significant.

The pattern was not perfectly linear. Restricted cubic spline analysis, a flexible statistical technique that allows the data to curve rather than forcing them into a straight line, detected a nonlinear relationship between PIV and metabolic syndrome, with a P value of 0.044 for nonlinearity. This suggests that the change in metabolic-syndrome odds may not be identical at every point on the PIV scale. In biological terms, inflammation could have different implications at relatively low, intermediate or very high levels, or the association could reflect interactions with obesity, insulin resistance, liver dysfunction, kidney disease or medication use. The analysis found a positive relationship across the PIV range, but the detailed shape of that relationship would need to be tested in prospective studies before it could guide clinical thresholds.

To examine whether the result was being driven by specific types of participants, the researchers performed stratified analyses across subgroups. The positive association between PIV and metabolic syndrome remained broadly consistent, rather than disappearing in one particular demographic or clinical category. The investigators also repeated the analysis after excluding people taking fibrates or omega-3 products, which can affect blood lipids, as well as medications used to lower blood glucose or blood pressure. In that restricted sample, the association became stronger, with an odds ratio of 1.73 and a 95 percent confidence interval from 1.26 to 2.38. This finding may indicate that treatment-related changes in metabolic measurements or blood-cell profiles had partly obscured the relationship in the full dataset, although it could also reflect differences between people who do and do not receive those medications.

The researchers tested additional definitions and methods to assess the robustness of their findings. PIV remained significantly and positively associated with metabolic syndrome when the condition was defined using the Harmonized criteria, an internationally developed approach that brings together several commonly used diagnostic thresholds. Missing data were also addressed using random forest imputation, a machine-learning method that estimates absent values from patterns in the observed data. With that approach, the association remained stable in the first three models but weakened in the most fully adjusted model. Such attenuation is important: it shows that the strength of the association can depend on how missing information and potential confounders are handled, even when the overall signal remains suggestive.

Metabolic syndrome has long been linked to chronic, low-grade inflammation. Excess visceral fat—the metabolically active fat stored around internal organs—can release inflammatory signaling molecules and attract immune cells. These signals may interfere with insulin action, promote abnormal lipid metabolism and impair the function of the vascular endothelium, the cell layer lining blood vessels. Insulin resistance can lead the pancreas to produce more insulin to maintain normal blood glucose, while the liver may continue releasing glucose and producing triglyceride-rich particles. At the same time, inflammation and oxidative stress can alter platelet activity and leukocyte behavior. A composite measure such as PIV could therefore reflect several biological processes that overlap with the development or expression of metabolic syndrome, although it cannot reveal which process comes first.

The potential appeal of PIV is practical as much as biological. Platelet and white-cell counts are routinely included in complete blood counts, making the components relatively inexpensive and widely available compared with specialized inflammatory assays. If future research confirms that PIV adds meaningful information beyond waist circumference, blood pressure, glucose and lipid measurements, it could become a supplementary risk marker for identifying people who warrant closer metabolic evaluation. But the current study is not sufficient to support that use. NHANES provides a powerful population snapshot, yet its cross-sectional design measures exposure and outcome at roughly the same time. The data cannot establish whether elevated PIV precedes metabolic syndrome, results from it, or is influenced by an unmeasured factor such as infection, smoking, diet, medication, chronic disease or socioeconomic conditions.

The authors, led by Qian Dai and colleagues at Shanghai Fifth People’s Hospital affiliated with Fudan University and Fudan University’s Center for Community-Based Health Research, conclude that higher PIV is positively associated with the presence of metabolic syndrome among U.S. adults. They emphasize that prospective cohort studies in diverse populations are needed to determine whether the biomarker can predict future metabolic syndrome and whether it offers advantages over established measures of inflammation and insulin resistance. Clinical trials would also be needed to learn whether changing PIV through lifestyle or medical treatment changes metabolic outcomes, rather than merely accompanying them. For now, the study adds PIV to a growing list of inflammation-related indicators connected with cardiometabolic health. Its most important message is not that a single blood index can replace standard screening, but that the immune system, blood cells and metabolism may be more tightly intertwined than conventional checkups reveal.

The relationship begins with anatomy. Blood from much of the intestine travels directly to the liver through the portal vein, carrying nutrients, microbial products and chemical signals absorbed across the intestinal wall. Under healthy conditions, the liver acts as a biochemical filter, while the intestinal barrier limits the passage of potentially harmful substances. This barrier is maintained by mucus, epithelial cells and protein complexes known as tight junctions, which seal the spaces between neighboring cells. When inflammation, infection, dietary stress or metabolic disease weakens these defenses, bacterial components can cross into the circulation and place the liver under sustained immune pressure.

Among the most important signals are pathogen-associated molecular patterns, or PAMPs, such as lipopolysaccharide from the outer membrane of Gram-negative bacteria. Damage-associated molecular patterns released by injured host cells can intensify the same response. In the liver, these molecules are detected by pattern-recognition receptors, including Toll-like receptors and NOD-like receptors, on immune cells and other hepatic cell types. Activation of these sensors stimulates transcription factors such as NF-κB and promotes the production of cytokines including tumour necrosis factor, interleukin-1β and interleukin-6. A short-lived response can be protective, but persistent signalling may drive chronic inflammation and fibrosis.

The review also highlights the microbiome as a chemical partner in gut–liver communication. Intestinal bacteria transform dietary components into short-chain fatty acids, including acetate, propionate and butyrate, which influence epithelial integrity, immune-cell activity and energy metabolism. Other microbial products can be harmful when produced in excess or insufficiently cleared. Changes in bacterial composition, known as dysbiosis, may increase the generation of ethanol, ammonia, indole derivatives or other metabolites that affect hepatic inflammation. The biological impact depends not only on which microbes are present, but also on their activity, the integrity of the intestinal barrier and the liver’s ability to process incoming compounds.

Bile acids create a second major communication circuit. Produced in the liver and released into the intestine, these molecules aid fat digestion before being modified by intestinal bacteria and returned through the enterohepatic circulation. Beyond their digestive role, bile acids act as signalling molecules through receptors such as the farnesoid X receptor and the G-protein-coupled bile acid receptor TGR5. These pathways help regulate lipid and glucose metabolism, immune responses and the composition of the microbiome. Disrupted bile-acid synthesis, transport or microbial conversion can therefore affect both intestinal inflammation and liver disease, linking metabolic disorders to changes in immune signalling.

This network becomes particularly important in conditions such as metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, inflammatory bowel disease and advanced liver fibrosis. In metabolic liver disease, excess dietary energy and insulin resistance can promote fat accumulation in hepatocytes, while microbial products and inflammatory mediators amplify cellular stress. Kupffer cells, the liver’s resident macrophages, respond to these signals and communicate with stellate cells. Once activated, stellate cells produce extracellular matrix proteins, including collagen, that gradually remodel liver tissue. Persistent matrix deposition can lead to fibrosis and, in severe cases, cirrhosis.

The authors describe the gut–liver axis as a therapeutic opportunity, but the review also suggests why simple solutions have often failed. Antibiotics may reduce selected bacterial signals but can disrupt beneficial communities and promote resistance. Probiotics and prebiotics can influence microbial ecology, although their effects may vary according to the patient’s diet, baseline microbiome and disease stage. Approaches under investigation include targeted microbial consortia, postbiotics, faecal microbiota transplantation, engineered bacteria and dietary strategies designed to restore production of protective metabolites. The central challenge is to modify the ecosystem precisely rather than suppressing it indiscriminately.

Drug development is also moving toward the molecular links that connect intestinal signals with hepatic inflammation. Potential targets include receptors that detect microbial products, enzymes involved in bile-acid metabolism, inflammatory cytokine pathways and mechanisms controlling epithelial tight junctions. Therapies designed to alter bile-acid signalling or reduce fibrogenic activation in the liver could potentially interrupt disease progression. However, the review emphasizes that the gut–liver axis is highly individualized. Sex, age, genetics, medication use, diet and environmental exposures can all influence microbial communities and immune responses, making broad treatment strategies difficult to apply uniformly.

Future progress may depend on combining multiple forms of biological information. Metagenomic sequencing can identify microbial genes, while metabolomics reveals the compounds actually produced in the intestine and transported to the liver. Imaging, immune profiling and computational modelling may then connect these molecular signals to tissue damage and clinical outcomes. Such integrated approaches could help distinguish harmless dysbiosis from the specific microbial and metabolic patterns that predict inflammation or fibrosis. The emerging picture is not of a single disease pathway, but of a dynamic network that can be measured, manipulated and, potentially, reset.

By bringing together immunology, microbiology, hepatology and metabolism, Murao, Aziz and Wang position inflammatory gut–liver crosstalk as a central problem in modern medicine. The review’s message is both cautionary and promising: damage in one organ can reverberate through the entire network, but that same connectivity creates several points for intervention. Treatments that protect the intestinal barrier, rebalance microbial chemistry and calm excessive hepatic immune activation could eventually offer more precise ways to prevent chronic liver disease before irreversible scarring develops.

Subject of Research: Inflammatory communication between the gut and liver, including the roles of the intestinal barrier, microbiome, microbial metabolites, bile acids, immune signalling and potential therapeutic targets.

Article Title: Inflammatory gut–liver crosstalk: mechanisms and therapeutic targets

Article References: Murao, A., Aziz, M. & Wang, P. “Inflammatory gut–liver crosstalk: mechanisms and therapeutic targets.” Experimental & Molecular Medicine (2026). https://doi.org/10.1038/s12276-026-01810-3

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01810-3

Keywords: gut–liver axis, intestinal barrier, microbiome, bile acids, inflammation, liver disease, fibrosis, microbial metabolites, immune signalling, therapeutic targets

Using infected mice to mimic key aspects of SFTS disease, the team evaluated whether ATRA could reduce the overwhelming immune activation associated with viral burden. Rather than simply slowing replication, the study emphasizes a broader immunomodulatory effect: ATRA reshaped host inflammatory signaling so that systemic cytokine production was curtailed.

At the cellular level, the authors focus on how innate immune pathways amplify inflammation during severe infection. By interfering with pro-inflammatory transcriptional programs, ATRA reduced signals that typically escalate during viral stress. This included down-tuning pathways that recruit and activate immune effectors, thereby lowering the intensity of systemic immune responses.

The findings also connect ATRA to platelet- and vascular-adjacent disease features seen in SFTS. Although the study centers on inflammation, controlling downstream immune overactivity can influence the physiological deterioration that accompanies severe disease. In this context, the work supports the idea that retinoid signaling can act as a host “brake” during infection-driven dysregulation.

Mechanistically, the study integrates retinoid biology with antiviral immunology, highlighting that ATRA can bias immune programs toward resolution rather than escalation. Such a shift is particularly relevant when inflammation becomes self-reinforcing and harmful, even as viral replication proceeds.

Importantly, the research frames ATRA as a candidate for translational exploration because retinoids are already established pharmacologically. That practical angle may speed early evaluation of dosing strategies that balance immune suppression with the need to control infection.

Overall, the study presents ATRA as a promising host-targeted approach to suppress systemic inflammatory pathology in SFTS. By converting damaging immune activation into a more controlled response, all-trans retinoic acid may offer a new direction for managing severe viral disease where inflammation is a central driver of morbidity.

Subject of Research: Severe fever with thrombocytopenia syndrome (SFTS) virus; systemic inflammation; host-directed immunomodulation
Article Title: All-trans retinoic acid suppresses systemic inflammation induced by severe fever with thrombocytopenia syndrome virus in mice
Article References: Yu, X., Wu, J., Yin, X. et al. All-trans retinoic acid suppresses systemic inflammation induced by severe fever with thrombocytopenia syndrome virus in mice. Nat Microbiol (2026). https://doi.org/10.1038/s41564-026-02411-6
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41564-026-02411-6

To explore these links, the team assessed fatigue severity alongside biological markers that can reflect immune activation, metabolic stress, and systemic inflammation. Such processes are often implicated in long-term outcomes after cancer, where recovery may involve chronic, low-grade biological disruption. By examining these factors together, the researchers sought patterns that could explain why some survivors experience more profound fatigue than others.

A key element of the study is its emphasis on correlating fatigue with biological readouts rather than relying solely on self-report. That strategy can help clarify whether fatigue corresponds to measurable changes in the body, potentially improving how clinicians identify at-risk patients. The analysis was designed to detect associations between fatigue and marker profiles, while considering relevant clinical context.

The findings suggest that fatigue is not just “in the head,” but may align with biological systems that stay altered after cancer. In practical terms, such correlates could support the development of screening approaches that flag fatigue risk using biomarker signatures. That, in turn, could guide targeted interventions and help prevent fatigue from becoming a long-term barrier to recovery.

From a technical standpoint, studies like this typically require careful normalization of biological measurements and statistical handling of multiple variables to avoid spurious associations. The goal is to distinguish fatigue-linked signals from background variation across individuals and cancer histories. While correlational by nature, the evidence can still sharpen hypotheses about underlying pathways.

Importantly, the research centers on older male survivors, a group that may face distinct biological aging effects alongside cancer survivorship. Understanding fatigue in this demographic is critical because age-related immune and metabolic changes could interact with treatment-related effects to shape persistent symptoms.

If confirmed and extended in larger cohorts, these biomarker associations could influence future clinical trials. They may also help stratify patients for fatigue-focused therapies, including anti-inflammatory strategies, metabolic support, or behavioral interventions tailored to biology.

Overall, the study provides a new biological angle on cancer-related fatigue, reinforcing a growing view in science news: survivorship symptoms can reflect measurable physiological states. With the DOI below, readers can access the original publication for full methodological details and results.

Subject of Research: Cancer-related fatigue biology in older male cancer survivors

Article Title: Biological correlates of cancer-related fatigue in older male cancer survivors.

Article References: Tundealao, S., Irwin, M.R., Cole, S. et al. Biological correlates of cancer-related fatigue in older male cancer survivors. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04274-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04274-1